private financing

The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.

The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.

One BioMed was spun out of Singapore's Agency for Science, Technology, and Research to  develop a point-of-care diagnostic platform for infectious disease.

The company develops assays and reagents for tissue-based biomarker research and discovery including its UltiMapper line of multiplexed assays.

The firm is developing a portable, rapid MDx platform for infectious disease testing in clinics, and anticipates launching a first product in 2020.

The companies signed an agreement earlier this year to jointly develop microbiome research services for international markets including a shotgun metagenomic sequencing-based service.

The Swedish company is developing sequencing- and PCR-based tests and services that quantify aberrations in DNA, RNA, and circulating tumor DNA.

This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.

The funds will support Curetis' R&D efforts, which include partnering its Unyvero A30 RQ mid-plex diagnostics system for verification and validation testing.